explore -WSS

explore

author：fashion 2025-09-28 01:39:00 - browse：693

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Cue Health's Covid

WSS

Diversity in clinical trials starts with building trust, experts say

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Stigma and the return of syphilis

Key Senate committee drafts bipartisan bill to stem drug shortages

Key Senate committee drafts bipartisan bill to stem drug shortages

Lab trade group sues FDA to halt regulation of lab

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

Bird flu outbreak in cows is latest avian flu curveball

Alkermes shareholders re

Element Biosciences CEO lays out genome sequencing strategy

Heart attack and stroke risk calculators need revising

Exact Sciences stock tumbles despite strong cancer detection sales

Wildfire smoke exposes gaps in outdoor worker protections

What will save rural psychiatry services? Higher Medicaid payments

In age of alternative facts, a scholarly course on calling out crap

Why does health care cost so much? A reading guide

explore

AI used to predict Covid

Heat waves linked to early deliveries, preterm births in new study

Akili, maker of video game for ADHD, to be acquired for 34 million

Heat waves linked to early deliveries, preterm births in new study

Bird flu outbreak in cows is latest avian flu curveball

Dark money group runs ads on China biotech bill

focus

hotspot

hotspot

entertainment